Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is listed today as Cabaletta Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2019 | $50 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2018 | $38 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cabaletta Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2019).
SEC Form D · Jan 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2019
That is all the official record says: Cabaletta Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cabaletta Bio, Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Partners V, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| 5AM Ventures V, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt IV, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Private Design Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Mark Simon | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Steven Nichtberger | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding Cabaletta Bio, Inc. shares, as of Sep 30, 2026.
- Jennison Associates LLC$48 M11.66%
- Bain Capital Life Sciences Investors, LLC$41 M9.83%
- T. Rowe Price Investment Management, Inc.$33 M8.00%
- BlackRock, Inc.$28 M6.67%
- Adage Capital Partners GP, L.L.C.$27 M6.57%
- State Street Corp$15 M3.73%
- Vanguard Capital Management LLC$14 M3.31%
- Price T Rowe Associates Inc /MD/$12 M2.89%
- Woodline Partners LP$10 M2.41%
- Alyeska Investment Group, L.P.$9 M2.09%
- Cormorant Asset Management, LP$9 M2.09%
- Geode Capital Management, LLC$8 M1.98%
- Goldman Sachs Group Inc$8 M1.98%
- Citadel Advisors LLC$5 M1.26%
- Heights Capital Management, Inc$5 M1.16%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dan Geffken | Executive officer | Jan 2019 |
| Steven Nichtberger | Executive officer | Jan 2019 |
| Brian Daniels | Director | Jan 2019 |
| Mark Simon | Director | Jan 2019 |
| Steven Nichtberger | Director | Jan 2019 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.